Published in J Pediatr Hematol Oncol on November 01, 2003
Unusual lower back pain with monocytosis: A case report. Oncol Lett (2016) 0.75
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
Estimation of α/β for late rectal toxicity based on RTOG 94-06. Int J Radiat Oncol Biol Phys (2011) 2.96
Impact of trough IgG on pneumonia incidence in primary immunodeficiency: A meta-analysis of clinical studies. Clin Immunol (2010) 2.93
Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys (2003) 2.58
Survival among men with clinically localized prostate cancer treated with radical prostatectomy or radiation therapy in the prostate specific antigen era. J Urol (2012) 2.24
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med (2003) 2.16
Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer (2013) 2.10
Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality/hormonal and sexual quality of life: results of a multicenter prospective study. Urology (2013) 2.08
Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys (2002) 1.85
PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys (2005) 1.83
Allergic dysregulation and hyperimmunoglobulinemia E in Foxp3 mutant mice. J Allergy Clin Immunol (2005) 1.75
Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. Int J Radiat Oncol Biol Phys (2012) 1.70
Statewide newborn screening for severe T-cell lymphopenia. JAMA (2009) 1.68
Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives. Ann Med (2006) 1.65
Development of a routine newborn screening protocol for severe combined immunodeficiency. J Allergy Clin Immunol (2009) 1.65
A phase I/II radiation dose escalation study with concurrent chemotherapy for patients with inoperable stages I to III non-small-cell lung cancer: phase I results of RTOG 0117. Int J Radiat Oncol Biol Phys (2010) 1.64
Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys (2006) 1.62
Long-term outcome in children treated for craniopharyngioma with and without radiotherapy. J Neurosurg Pediatr (2008) 1.59
Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging (2005) 1.52
Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatr Blood Cancer (2010) 1.45
Tools for consensus analysis of experts' contours for radiotherapy structure definitions. Radiother Oncol (2010) 1.36
Predicting dose-volume histograms for organs-at-risk in IMRT planning. Med Phys (2012) 1.35
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology (2008) 1.32
Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys (2007) 1.32
Newborn screening for severe combined immunodeficiency; the Wisconsin experience (2008-2011). J Clin Immunol (2011) 1.25
Granzyme B and the downstream granzymes C and/or F are important for cytotoxic lymphocyte functions. J Immunol (2005) 1.24
Cause-specific mortality and second cancer incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood (2008) 1.21
Impact of radiation and chemotherapy on risk of dental abnormalities: a report from the Childhood Cancer Survivor Study. Cancer (2009) 1.19
Short delay in initiation of radiotherapy may not affect outcome of patients with glioblastoma: a secondary analysis from the radiation therapy oncology group database. J Clin Oncol (2008) 1.17
Glioblastoma in children: a single-institution experience. Int J Radiat Oncol Biol Phys (2011) 1.16
Implementing routine testing for severe combined immunodeficiency within Wisconsin's newborn screening program. Public Health Rep (2010) 1.15
Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol (2011) 1.12
Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma: Radiation Therapy Oncology Group Trial 98-03. Int J Radiat Oncol Biol Phys (2008) 1.10
Age as an independent prognostic factor in patients with glioblastoma: a Radiation Therapy Oncology Group and American College of Surgeons National Cancer Data Base comparison. J Neurooncol (2011) 1.09
Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J Oncol Pract (2013) 1.05
Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant (2009) 1.04
Childhood and adolescent thyroid carcinoma. Cancer (2002) 1.04
Postoperative radiation therapy for grade II and III intracranial ependymoma. Int J Radiat Oncol Biol Phys (2005) 1.03
Treatment of children and adolescents with localized parameningeal sarcoma: experience of the Intergroup Rhabdomyosarcoma Study Group protocols IRS-II through -IV, 1978-1997. Med Pediatr Oncol (2002) 1.03
Phase III multi-institutional trial of adjuvant chemotherapy with paclitaxel, estramustine, and oral etoposide combined with long-term androgen suppression therapy and radiotherapy versus long-term androgen suppression plus radiotherapy alone for high-risk prostate cancer: preliminary toxicity analysis of RTOG 99-02. Int J Radiat Oncol Biol Phys (2008) 1.03
Differential effects of radiotherapy on growth and endocrine function among acute leukemia survivors: a childhood cancer survivor study report. Pediatr Blood Cancer (2012) 1.02
Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol (2008) 1.01
Physical impairment and social adaptation in adult survivors of childhood and adolescent rhabdomyosarcoma: A report from the Childhood Cancer Survivors Study. Psychooncology (2007) 1.01
Long term outcome with post-operative radiation therapy for spinal canal ependymoma. J Neurooncol (2007) 1.00
Do intermediate radiation doses contribute to late rectal toxicity? An analysis of data from radiation therapy oncology group protocol 94-06. Int J Radiat Oncol Biol Phys (2012) 1.00
Event (error and near-miss) reporting and learning system for process improvement in radiation oncology. Med Phys (2010) 0.98
Safety and efficacy of enzyme replacement therapy in combination with hematopoietic stem cell transplantation in Hurler syndrome. Genet Med (2005) 0.97
Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. Int J Radiat Oncol Biol Phys (2013) 0.96
Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Cancer (2013) 0.94
Future vision for the quality assurance of oncology clinical trials. Front Oncol (2013) 0.93
Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy (2007) 0.90
Practical method of adaptive radiotherapy for prostate cancer using real-time electromagnetic tracking. Int J Radiat Oncol Biol Phys (2011) 0.89
The effect of radiation timing on patients with high-risk features of parameningeal rhabdomyosarcoma: an analysis of IRS-IV and D9803. Int J Radiat Oncol Biol Phys (2013) 0.88
Cytomegalovirus viremia associated with death or retransplantation in pediatric lung-transplant recipients. Transplantation (2003) 0.87
Granzyme B regulates antiviral CD8+ T cell responses. J Immunol (2011) 0.86
Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology (2006) 0.86
Sudden unexplained hemolysis occurring in an infant due to presumed Loxosceles envenomation. J Emerg Med (2003) 0.86
A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood. Neuro Oncol (2013) 0.85
Immunosuppressive effects in infants treated with corticosteroids for infantile hemangiomas. Arch Dermatol (2010) 0.85
Radiation therapy for increasing prostate-specific antigen levels after radical prostatectomy. Clin Prostate Cancer (2003) 0.85
A research agenda for radiation oncology: results of the radiation oncology institute's comprehensive research needs assessment. Int J Radiat Oncol Biol Phys (2012) 0.84
Late onset hearing loss: a significant complication of cancer survivors treated with Cisplatin containing chemotherapy regimens. J Pediatr Hematol Oncol (2010) 0.83
Adaptive radiation therapy for postprostatectomy patients using real-time electromagnetic target motion tracking during external beam radiation therapy. Int J Radiat Oncol Biol Phys (2012) 0.83
Oligodendrogliomas in children. J Neurooncol (2011) 0.82
Multiplexed quantitative real-time PCR to detect 22q11.2 deletion in patients with congenital heart disease. Physiol Genomics (2010) 0.82
Granzymes A and B are not expressed in human neutrophils. Blood (2004) 0.82
Use of fractional dose-volume histograms to model risk of acute rectal toxicity among patients treated on RTOG 94-06. Radiother Oncol (2012) 0.79
Optimal equations for describing the relationship between prostate volume, number of sources, and total activity in permanent prostate brachytherapy. Am J Clin Oncol (2010) 0.79
Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol. Brachytherapy (2006) 0.78
Inter-institutional variation of implant activity for permanent prostate brachytherapy. Brachytherapy (2008) 0.78
Evaluation of 3 T pelvic MRI imaging in prostate cancer patients receiving post-prostatectomy IMRT. World J Urol (2014) 0.77
Safety and efficacy of prolonged cytomegalovirus prophylaxis with intravenous ganciclovir in pediatric and young adult lung transplant recipients. Pediatr Transplant (2007) 0.76
Do not count out external-beam radiation therapy for high-risk prostate cancer. J Clin Oncol (2010) 0.75
Comparison of dose decrement from intrafraction motion for prone and supine prostate radiotherapy. Radiother Oncol (2012) 0.75
Corrigendum: The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet (2015) 0.75
RSV infection--an immune balancing act: commentary on the article by Bem et al. on page 650. Pediatr Res (2008) 0.75
Late toxicity of a novel allogeneic stem cell transplant using single fraction total body irradiation for hematologic malignancies in children. J Pediatr Hematol Oncol (2015) 0.75
Uncertainties in radiation therapy: target volume definition in prostate cancer. Rays (2004) 0.75
New Developments in Radiation Oncology. Mo Med (2015) 0.75
A comparative study based on image quality and clinical task performance for CT reconstruction algorithms in radiotherapy. J Appl Clin Med Phys (2016) 0.75
Otolaryngological manifestations of posttransplant lymphoproliferative disorder in pediatric thoracic transplant patients. Int J Pediatr Otorhinolaryngol (2005) 0.75
Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation. J Am Acad Dermatol (2008) 0.75
Three-dimensional conformal therapy versus standard radiation therapy in localized carcinoma of prostate: an update. Clin Prostate Cancer (2002) 0.75
Cellular and genetic basis of primary immune deficiencies. Pediatr Clin North Am (2006) 0.75
Common variable immunodeficiency with regulatory T-cell deficiency treated with rapamycin. Ann Allergy Asthma Immunol (2009) 0.75
Dose escalation in locally advanced carcinoma of the prostate. Semin Radiat Oncol (2003) 0.75
The efficacy of radiation therapy in the management of grade I astrocytomas. J Neurooncol (2005) 0.75